Form 8-K - Current report:
SEC Accession No. 0001641172-25-018808
Filing Date
2025-07-11
Accepted
2025-07-11 17:10:00
Documents
13
Period of Report
2025-07-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 49390
  Complete submission text file 0001641172-25-018808.txt   244460

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cldi-20250709.xsd EX-101.SCH 3075
3 XBRL DEFINITION FILE cldi-20250709_def.xml EX-101.DEF 26199
4 XBRL LABEL FILE cldi-20250709_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE cldi-20250709_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3860
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 251119619
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)